Opus Genetics, Inc. (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients ...

A 6-year-old girl with a rare inherited blindness regained vision through gene therapy, helping her see in low light again.

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

Opus Genetics, Inc. (Nasdaq: IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene ...

A revolutionary eye implant invented by a Stanford University scientist is giving some blind adults the ability to read, ...

The firm announced it has aligned with the US Food and Drug Administration on the design of the Phase III study, which could support a biologics license application.

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative ...

LOCAL entrepreneur Dr Terry Cross has supported the delivery of specialist, sight-saving equipment to the Children’s Eye Unit ...

A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug ...

The Food and Drug Administration recently approved gene therapy to treat sickle cell disease among children ages 2 and older, ...

A surprising discovery is reshaping scientists' understanding of how humans develop sharp central vision before birth.

Piotr Woźniak, MD, PhD, shares real-world evidence on Artelac Complete in dry eye disease from EuDEC 2026 in Milan, Italy, including improvements in tear break-up time and Schirmer scores, ...